- Globus Medical has reaffirmed its financial guidance for Fiscal Year 2025.
- The company maintains its forecast for non-GAAP fully diluted earnings per share to be between $3.00 and $3.30, with an estimate of $3.15.
- Keith Pfeil has been named as CEO, following the resignation of former CEO Daniel Scavilla.
- Kyle Kline has been appointed as the new CFO of Globus Medical.
- For the second quarter of 2025, sales are anticipated to be approximately $745.3 million, marking an 18.4% increase over the same period in 2024.
- Excluding the contribution from the recently acquired Nevro, Inc., base business sales are expected to reach about $650.8 million, reflecting a 3.3% increase over the second quarter of 2024.
- The US Spine business of Globus Medical experienced a 7.4% growth on a day-adjusted basis compared to the previous year.
- There was a notable sequential improvement in Enabling Technology sales in the second quarter.
- The company has received 10 buy ratings, 6 hold ratings, and no sell ratings from analysts.
Globus Medical Inc A on Smartkarma
Analysts on Smartkarma, such as Baptista Research, have been closely covering Globus Medical Inc A, providing valuable insights into the company’s recent performance and strategic decisions. In a report titled “Globus Medical’s $250M Nevro Bet: Can This Bold Acquisition Disrupt Neuromodulation?“, Baptista Research discusses Globus Medical’s first quarter of 2025, highlighting both strengths and challenges. The report notes a slight decline in revenue on a constant currency basis, attributed to softer sales in enabling technology, supply chain disruptions, and the timing of international distributor orders.
Furthermore, Baptista Research‘s report “Globus Medical: Nevro Acquisition & Market Expansion Driving Our ‘Outperform’ Rating!” applauds Globus Medical’s performance in 2024. The company achieved record revenue of $2.519 billion, indicating a significant 61% increase from the previous year. Additionally, the non-GAAP EPS saw a substantial rise to $3.04, despite a 20% expansion in diluted shares. This positive performance has led analysts to give an ‘Outperform’ rating, showcasing confidence in Globus Medical’s market expansion strategies.
A look at Globus Medical Inc A Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 1 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 2.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Globus Medical Inc A appears to have a mixed long-term outlook. With a value score of 3, the company is seen as fairly valued in the market. Its growth score of 3 indicates potential for future expansion, while the resilience score of 4 suggests the company’s ability to weather economic challenges. However, with a dividend score of 1, investors may not expect significant dividend payouts. The momentum score of 2 reflects a moderate trend in the company’s stock performance.
Globus Medical, Inc. is a medical device company specializing in products that aid in the healing of spine disorders. Focused on innovative fusion and disruptive technologies, the company is dedicated to developing and commercializing solutions that improve patient outcomes in the field of spine care.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
